CINECA IRIS Institutional Research Information System

CREMOLINI, CHIARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 19.786
AS - Asia 11.201
EU - Europa 6.812
SA - Sud America 2.411
AF - Africa 502
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 10
Totale 40.742
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 19.266
SG - Singapore 3.728
CN - Cina 2.674
IT - Italia 2.450
HK - Hong Kong 2.395
BR - Brasile 1.987
VN - Vietnam 886
SE - Svezia 841
DE - Germania 694
BG - Bulgaria 632
GB - Regno Unito 503
RU - Federazione Russa 369
CA - Canada 329
FI - Finlandia 284
IN - India 256
TR - Turchia 242
FR - Francia 220
KR - Corea 186
AT - Austria 170
JP - Giappone 163
AR - Argentina 155
CI - Costa d'Avorio 155
UA - Ucraina 148
NL - Olanda 129
BD - Bangladesh 126
ID - Indonesia 105
IQ - Iraq 91
PL - Polonia 91
MX - Messico 90
ZA - Sudafrica 87
EC - Ecuador 57
CH - Svizzera 56
SN - Senegal 55
NG - Nigeria 49
PK - Pakistan 46
VE - Venezuela 46
ES - Italia 44
CO - Colombia 43
PY - Paraguay 42
SA - Arabia Saudita 42
UZ - Uzbekistan 40
MA - Marocco 34
BE - Belgio 32
KE - Kenya 27
CL - Cile 26
EG - Egitto 25
UY - Uruguay 24
CZ - Repubblica Ceca 22
PE - Perù 22
AE - Emirati Arabi Uniti 21
TN - Tunisia 19
LT - Lituania 18
NP - Nepal 17
MY - Malesia 16
OM - Oman 16
AU - Australia 15
IE - Irlanda 15
PH - Filippine 15
HN - Honduras 14
TW - Taiwan 14
IL - Israele 12
IR - Iran 11
JM - Giamaica 11
JO - Giordania 11
PA - Panama 11
TT - Trinidad e Tobago 11
AZ - Azerbaigian 10
BB - Barbados 10
BJ - Benin 10
DZ - Algeria 10
AL - Albania 9
BO - Bolivia 9
CR - Costa Rica 9
DO - Repubblica Dominicana 9
PT - Portogallo 9
RO - Romania 9
GR - Grecia 8
KG - Kirghizistan 8
KZ - Kazakistan 8
LB - Libano 8
PS - Palestinian Territory 8
KH - Cambogia 7
DK - Danimarca 6
ET - Etiopia 6
EU - Europa 6
NI - Nicaragua 6
NO - Norvegia 6
QA - Qatar 6
AO - Angola 5
BY - Bielorussia 5
EE - Estonia 5
LU - Lussemburgo 5
MK - Macedonia 5
NZ - Nuova Zelanda 5
SK - Slovacchia (Repubblica Slovacca) 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
TH - Thailandia 5
LA - Repubblica Popolare Democratica del Laos 4
LV - Lettonia 4
Totale 40.666
Salva come PNG Salva come JPEG
Città #
Hong Kong 2.366
Ashburn 2.131
Woodbridge 1.995
Singapore 1.845
Fairfield 1.614
Ann Arbor 1.424
Santa Clara 1.298
Houston 1.285
Chandler 1.087
Dallas 1.059
Shanghai 753
Seattle 719
Sofia 628
Wilmington 593
Cambridge 586
Milan 565
New York 547
Beijing 494
Boardman 449
Los Angeles 355
Hefei 308
Princeton 297
Lawrence 283
Ho Chi Minh City 237
Medford 235
Ottawa 228
Seoul 180
Florence 179
Pisa 177
São Paulo 162
London 161
Abidjan 154
Dearborn 152
Des Moines 146
Jacksonville 139
Munich 137
Redondo Beach 137
Nanjing 129
Tokyo 128
Serra 121
Vienna 121
Buffalo 120
Istanbul 113
Rome 112
Hanoi 108
Düsseldorf 104
Dong Ket 97
Cascina 92
San Diego 83
Warsaw 82
Izmir 81
Frankfurt am Main 74
Ogden 74
Rio de Janeiro 71
Turku 63
Nuremberg 61
Bremen 60
Lancaster 59
Redwood City 59
Dakar 54
Chicago 50
Genoa 50
Nanchang 50
Belo Horizonte 49
Lagos 47
Bern 46
Lappeenranta 44
Seacroft 41
Turin 41
Kunming 40
Johannesburg 39
Phoenix 39
Shenyang 39
Boulder 38
Helsinki 38
Naples 37
Baghdad 36
Dhaka 36
Haiphong 35
Fuzhou 34
Tashkent 33
Brasília 32
Chennai 32
Jüchen 31
Montreal 31
Norwalk 31
Hebei 30
Jakarta 30
Marseille 29
Brussels 28
Council Bluffs 28
Orem 28
Stockholm 28
Guangzhou 27
Mumbai 27
Boston 26
Hyderabad 26
Porto Alegre 26
The Dalles 26
Toronto 26
Totale 28.575
Salva come PNG Salva come JPEG
Nome #
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 212
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan 209
OUTCOME OF SECOND-LINE TREATMENT AFTER FIRST-LINE CHEMOTHERAPY WITH THE GONO FOLFOXIRI REGIMEN. 205
TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group 197
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients 194
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 192
Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer 188
Prevention and management of adverse events related to regorafenib 179
Analysis of PTEN expression and KRAS mutations on primaries (PRIM) and metastases (METS) to predict benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 178
Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: evaluation of the effects of switched schedules and related pharmacodynamics 178
Pten expression and Kras mutations as predictors of benefit from cetuximab plus irinotecan (CETIRI) in metastatic colorectal cancer (MCRC) patients (PTS) 176
Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials 176
KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 175
KRAS codon 61, 146 and BRAF V600E mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer 174
Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients 172
Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer 172
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 172
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 172
Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis 171
TAS-102 for the treatment of metastatic colorectal cancer 171
BRAF V600E mutation and Amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 169
DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer 169
Circulating tumor DNA analysis in colorectal cancer: From dream to reality 169
Pattern of recurrence and survival after D2 right colectomy for cancer: is there place for a routine more extended lymphadenectomy? 168
ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer 168
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 168
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle 167
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 166
Association of BRAF mutations and EGFR Intron-1 L/L genotype with resistance to cetuximab plus irinotecan treatment in KRAS wild-type metastatic colorectal cancer patients 165
Circulating amphiregulin (AR) plasma levels as surrogate pharmacodynamic markers of EGFR inhibition with cetuximab in metastatic colorectal cancer (MCRC) patients 164
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (mCRC) patients 164
Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO 163
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer 163
Exploratory analysis of circulating pro-and anti-angiogenic factors in metastatic colorectal cancer (MCRC) patients, treated with GONO-folfoxiri plus bevacizumab (BV) 161
BRAF V600E mutation and amphiregulin (AR) immunohistochemical expression in the prediction of benefit from cetuximab plus irinotecan in KRAS wild-type metastatic colorectal cancer (MCRC) patients 161
VEGF gene polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) 159
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. 159
Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials 159
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials 158
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 158
Case-report: folfoxiri plus bevacizumab in "poor-risk" liver-only metastatic colorectal cancer: case report and state-of-the-art. 157
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer 157
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus beva s first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. 156
Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3 156
Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial. 155
VEGF gene polymorphisms in the prediction of benefit from first-line folfiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 154
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 154
High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice 153
Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts). 152
Host genetic variants in the Insulin Growth Factor Binding Protein-3 impact on servival of patients with advanced gastric cancer treated with palliative chemotharapy 151
Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer 151
Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer 151
Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients 151
KRAS and BRAF mutational analyses in a phase II trial of first-line folfoxiri plus bevacizumab (BV) in metastatic colorectal cancer (MCRC) patients (pts) 150
Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients 150
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial 150
Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer 149
Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation 149
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients 149
First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm 148
High activity and resection rate in molecularly selected patients with unresectable metastatic colorectal cancer (MCRC) treated with panitumumab (P) and folfoxiri as first-line therapy : a phase II study. 148
Quantitative evidence for early metastatic seeding in colorectal cancer 148
BRAF-mutated metastatic colorectal cancer between past and future 147
KRAS and BRAF genotyping of synchronous colorectal carcinomas. 147
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 147
The landscape of alterations in DNA damage response pathways in colorectal cancer 147
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib 146
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III “BEBYP”trial by the Gruppo Oncologico Nord Ovest (GONO). 145
Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer 145
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 144
Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial 143
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 142
Prospective analysis of the early modulation of plasma amphiregulin (AR) during treatment with cetuximab and irinotecan in irinotecan-refractory metastatic colorectal cancer (mCRC) patients (pts). 142
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer 141
FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). 141
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: A clinical and molecular proof of concept study 141
Location of primary tumor and benefit from anti-epidermal growth factorreceptor monoclonalantibodies in patients with RAS and BRAF wild-typemetastatic colorectal cancer 141
Prognostic significance of KRAS mutation rate in metastatic colorectal cancer patients. 140
A still missing piece of the FIRE-3 puzzle 140
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3 140
Risk for developing brain metastases from colorectal cancer in long-term survivors with lung metastases and KRAS mutations. 138
Biomarkers and response to bevacizumab--letter 138
Prevention of capecitabine toxicity using a 5-FU test dose 138
Histopathologic response to FOLFOXIRI plus bevacizumab of liver metastases from colorectal cancer. 138
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected 138
Amphiregulin (AR) expression in the prediction of benefit from cetuximab plus irinotecan in K-RAS wild-type metastatic colorectal cancer (mCRC) patients 137
Do we need biopsies of metastases for colorectal cancer patients? 137
Histopathological response to folfoxiri plus bevacizumab of liver metastases from colorectal cancer. 137
Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer 137
Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer 137
Primary Tumor Sidedness and Benefit from FOLFOXIRI plus Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer 137
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer 137
Atypical RAS mutations in metastatic colorectal cancer 137
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 137
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patients 136
Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer 136
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells 136
Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients 136
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 135
Estimating 12-weeks death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram 135
Totale 15.596
Salva come PNG Salva come JPEG
Categoria #
all - tutte 129.715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 129.715
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.572 0 0 0 0 0 321 109 143 286 138 133 442
2021/20222.601 36 91 40 73 464 478 52 82 184 172 162 767
2022/20233.384 450 433 219 330 336 418 43 210 597 34 281 33
2023/20243.584 291 330 509 233 474 516 264 97 177 134 202 357
2024/202511.587 167 400 171 461 900 1.200 948 588 1.204 1.434 1.261 2.853
2025/20268.502 855 1.666 1.684 1.735 1.400 1.162 0 0 0 0 0 0
Totale 41.659